#Juvenile Idiopathic Arthritis Treatment Market Trends | Explore Tumblr Posts and Blogs

healthcareanna · 24 days

Text

Biosimilars Market Size, Trends, Growth Analysis 2032

Biosimilars Market Overview

An integral component of the Biosimilars Market is the emergence of follow-on biologics. These biologics, which closely resemble existing biologic drugs, offer additional options for patients and healthcare providers. Follow-on biologics undergo rigorous testing to demonstrate similarity to the reference product, ensuring interchangeability and therapeutic equivalence. With their introduction, follow-on biologics stimulate competition in the biopharmaceutical industry, driving down prices and promoting innovation. As the demand for cost-effective biologic therapies continues to grow, the Biosimilars Market stands to benefit from the availability and acceptance of follow-on biologics, expanding treatment options and improving patient outcomes.

According to Market Research Future (MRFR), the biosimilars market insights was valued at USD 29.7 billion in 2023 and is projected to grow from USD 36.79 Billion in 2024 to USD 161.95 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 20.35% during the forecast period (2024 - 2032).

Biosimilars Market: Latest News and Developments

The FDA has approved the first Humira biosimilar. Adalimumab-bwwd (Cyltezo), a Humira biosimilar, received FDA approval in January 2023 for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.

Rising use of biosimilars in the treatment of cancer. A growing number of biosimilars are being used to treat cancer. The FDA authorised filgrastim-sndz (Zarxio), pegfilgrastim-jmdb (Onpro), and trastuzumab-dkst (Herzuma) as three biosimilars for the treatment of cancer in 2022.

Market Segmentation

Biosimilars industry can be considered with respect to product, applications, and end users.

The products based on which the market has been split into are recombinant glycosylated proteins, recombinant peptides, and recombinant non-glycosylated proteins. Recombinant non-glycosylated proteins are the biggest segment in the global market, thanks to the soaring cases of chronic disorders ranging from growth hormone deficiency to diabetes. As a result, recombinant non-glycosylated proteins are therapeutically used as they are readily available and are cost-effective.

Application-wise, the biosimilars market caters to chronic diseases, oncology, blood disorders, autoimmune diseases, infectious diseases, growth hormone deficiency, and more. Blood disorders have emerged as the top segment, as a result of the rising burden of the condition worldwide and the increased use of biosimilars by virtue of their low cost and the overall reduction in the treatment cost.

Major end users in the global market are hospitals and clinics as well as research institutes. Hospital and clinics are healthcare settings where treatment options and skilled professionals are easily available, and therefore, have emerged as the leading segment in the global industry.

Regional Status

Europe, MEA or Middle East & Africa along with the Americas, APAC or Asia Pacific are the primary markets for biosimilars.

Europe has taken the lead in the global market, as the region houses a vast elderly pool, with close to one fifth of the overall EU population aged more than 65 years. This has given way to several lifestyle-related disorders such as oncology, autoimmune diseases, diabetes, to name a few. Presumably, the scenario has raised the demand for biosimilars and can mean higher market growth over the next few years. In addition to this, numerous blockbuster biologics are on track to lose patent in the coming years, which should present lucrative opportunities to the biosimilar manufacturers.

The North American market displays a bright outlook and can emerge quite lucrative in the coming years, in view of the surging burden of chronic ailments in Canada and the United States. The rising spending on research activities by the healthcare agencies also fuels the market expansion in the region. Favorable reimbursement landscape in the region, especially in the US, encourages healthy competition as it results in lower incentives for the players to compete based on price.

The APAC market is slated to witness considerable growth, with China, South Korea and India offering a host of lucrative opportunities for drug development as well as commercialization. These are generics-driven countries and are known for frequently launching new and advanced manufacturing platforms, which has brought down the costs associated with biosimilar production. In the coming few years, majority of the patent expiries is touted to be in biosimilars, which is deemed as a profitable aspect by leading manufacturers and can translate into substantial market growth.

Eminent Vendors

Top global key players listed by biosimilars market outlook report include Stada Arzneimittel AG (Germany), Teva Pharmaceuticals (Israel), Biocon (India), Pfizer (US), Sandoz International (Germany), Eli Lily & Company (US), Actavis, Inc. (US), Dr. Reddy’s Laboratories (India), Cipla Ltd (India), Amgen, Inc. (US), Samsung Biologics (South Korea), Hospira Inc.(US), Mylan, Inc.(US), Celltrion (South Korea), to mention a few.

More Related Trending Topics

Medical Foods market

Insomnia market

Blockchain Technology in Healthcare market

Drug Device Combination market

Prefilled Syringes market

#healthcare #medical #health #medical devices #Biosimilars Market Size

0 notes

dbmr-blog-news · 5 months

Text

#Rheumatoid Arthritis Treatment Market

0 notes

pranalipawarshinde · 3 years

Text

Biosimilar Market Research Insights Shared in Detailed Report Forecast 2019-2027

Biosimilars Market: Introduction

Biosimilars can be defined as a biologic medical product, which is considered to be similar to already approved biologic. These biosimilars are approved based on their efficacy, quality, safety, and the same standards of pharmaceutical quality that apply to all biologic medicines. Chronic disease prevalence has been increasing significantly at the global level. This necessitates the need for affordable treatment, contributing to the growth of the biosimilars market.

High Demand for Recombinant Non-glycosylated Protein Biosimilars

In terms of product, the recombinant non-glycosylated proteins segment is likely to account for a major share of the global biosimilars market. Moreover, the insulin sub-segment of the recombinant non-glycosylated proteins segment dominated the market in 2018. It is likely to grow at a high CAGR during the forecast period, due to increase in prevalence of diabetes globally. According to the International Diabetes Federation, over 463 million adults aged between 20 years and 79 years lived with diabetes in 2019.

Request Brochure:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=118

Biosimilars for Oncology Indication to Dominate Global Market

In terms of indication, the global biosimilars market has been divided into chronic diseases, oncology, autoimmune diseases, infectious diseases, blood disorders, growth hormone deficiency, and others. The oncology segment held the largest market share in 2018 and the trend is anticipated to continue during the forecast period. The robust growth of the segment can be attributed to rise in prevalence of cancer cases globally. According to the World Cancer Research fund, over 18 million cancer cases were reported in 2018. In addition, the patent expiration of a range of cancer biologic drugs, leading to the growing usage of biosimilars, owing to their lower costs contributes to the growth of the segment in the forecast period.

Biosimilars Market: Prominent Regions

In terms of region, the global biosimilars market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe dominated the global biosimilars market in 2018. This can be attributed to the significant price reduction in biosimilars as compared to biologics, and country policies in Europe enabling the penetration of biosimilars to enhance patient access to affordable treatment, contributes to the growth of the market in Europe.

The biosimilars market in Asia Pacific is likely to expand at a rapid CAGR from 2019 to 2027. Increase in population of Asian countries, rise in urbanization, surge in aging population, lifestyle changes, and growing incidence of non-communicable diseases such as diabetes, cancer, and autoimmune diseases are driving the biosimilars market in Asia Pacific. Furthermore, various countries in South Asia have been assigning a major portion of their medical research budget for the development of biosimilars.

Request for covid19 Impact Analysis:https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=118

Biosimilars Market: Key Strategies

· The global biosimilars market is consolidated in terms of number of players. Key players operating in the global biosimilars market include Pfizer, Inc., Intas Pharmaceuticals Ltd., Biocon, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (A Novartis Division), Celltrion Inc., Amgen, Inc., STADA Arzneimittel AG, and Apotex Inc. (Apobiologix).

· These players have adopted various strategies such as product portfolio expansion, investment in research & development, collaborations, and product launches to establish a strong geographic presence. For instance, in November 2019, Pfizer received the U.S. FDA approval for its ABRILADA, a biosimilar to Humira, for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis, and plaque psoriasis.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/cardiovascular-proximal-anastomosis-devices-market-to-reach-us-23-6-mn-by-2030--says-tmr-report-301494327.html

https://www.prnewswire.com/news-releases/albumin-market-to-rise-at-cagr-of-6-2-during-forecast-period-observes-tmr-study-301500236.html

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants uses proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: [email protected]

Website: https://www.transparencymarketresearch.com/

0 notes

digitalconvo · 4 years

Text

Insulin Biosimilars Market Detailed Analysis and Forecast 2018-2028

Global Insulin Biosimilars Market: Overview

It is just handful of companies that are into the distribution and manufacturing of most of the insulin used in the developed countries. A number of new market players have developed its insulin making capacities and such a development is based on the methods of modern biotechnology.

The global insulin biosimilars market gathers its momentum from the increasing prevalence of diabetes. According to a report of World Health Organization (WHO), around 422 Mn adults are suffering from diabetes and around 1.5 million people have been killed by diabetes in the 2012. Insulin biosimilar can improve the access to treatment of diabetes mellitus amongst the diabetic patients. It also lessens the cost of treatment.

The global insulin biosimilars market has been segmented on the basis of type, disease indication, and region. The main objective of providing such a comprehensive report is to provide a deep insight into the market.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6148

Global Insulin Biosimilars Market: Notable Developments

The global insulin biosimilars market has witnessed quite a few developments over the last few years. These market developments suggest a trend and give an idea about the growth factors of the global insulin biosimilars market. One such development is mentioned below:

In 2016, the U.S-based Momenta Pharmaceuticals, Inc. revealed that it has formed a global collaboration agreement with the US-based Mylan N.V. The collaboration is aimed at commercializing, manufacturing, and developing six of Momenta Pharmaceutical’s present biosimilar candidates. The collaboration also comprised ORENCIA, one of its prominent biosimilar candidates. It is used for the treatment of moderate to severe adult psoriatic arthritis, juvenile idiopathic arthritis, and adult rheumatoid arthritis.

Some of the key market players of the global insulin biosimilars market are

Eli Lilly and Company

H. Boehringer Sohn AG & Ko. KG

Novo Nordisk A/S

Wockhardt Ltd.

Momenta Pharmaceuticals, Inc.

Ypsomed AG

Global Insulin Biosimilars Market: Growth Drivers

Rapid Rise in the Prevalence of Diabetes Worldwide Accentuates its Demand

Biosimilar insulins are made in such a way that it remains extremely similar to the original product. With the rise in the number of biosimilar insulin manufacturers, the offering of clinical aid similar to the present analogs of insulin at a more reasonable price has become possible. In addition, many insulin manufacturing firms are likely to lose their patents quite soon, which is likely to offer ample growth opportunities for the global insulin biosimilars market.

Furthermore, low pricing of biosimilar insulin meant for the treatment of diabetes along with its effectiveness is anticipated to open up new vistas of growth for the global insulin biosimilars market. Several companies are emphasizing on the development of medical devices that enable less painful and self delivery of biosimilar insulin. Such a factor is expected to propel the growth of the global insulin biosimilars market.

Expanding pool of geriatric population with arthritis and growing demand for fast acting insulin analogues is another booster for the market. Increased investment by government agencies on the research and development activities pertaining to insulin biosimilars is providing ample scope of development for the market.

To get Incredible Discounts on this Report, Click Here @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=6148

Global Insulin Biosimilars Market: Regional Outlook

In terms of region, the global insulin biosimilar market is split into the key regions of Middle East and Africa, North America, Europe, Asia Pacific, and Latin America. Of all the geographical segments, it is expected that North America will reign over the global insulin biosimilar market in the forthcoming years. High demand for insulin biosimilars amidst increasing prevalence of diabetes is likely to propel growth of the market in years to come.

Asia Pacific is prophesized to come up as a rapidly growing region in the market due to expanding pool of diabetic patients and changing lifestyle of the people. High competitiveness amongst the companies in the region is expected to further lower the price, thereby propelling the market toward growth.

The global insulin biosimilars market is segmented as:

Type

Rapid Acting Biosimilars

Long Acting Biosimilars

Premixed Biosimilars

Disease Indication

Type 1 Diabetes

Type 2 Diabetes

Request For TOC @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6148

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research, 3739 Balboa St # 1097, San Francisco, CA 94121 United States

Tel: +1-415-520-1050

0 notes

healthcare00897 · 6 years

Text

Biosimilars Market Necessity And Demand 2018 to 2026

Biosimilars are biopharmaceutical drug having active components, which are similar to one that has previously been licensed. They are identical copies of the original products and can be manufactured only when the patent for the original innovator product expires. Biologics or biosimilars are sensitive to changes in manufacturing process due to the higher molecular complexity.

Biosimilars are generally derived from living cells of plants, animals, yeast, bacteria and viruses, through genetic engineering processes including controlled gene expression and recombinant DNA technology. In 2010, the Food and Drug Administration (FDA) approved biosimilars as a part of Patient Protection and Affordable Care Act. The approval process is based on thorough demonstration of similarity and comparability with existing approved product.

Patent expiry of drugs and increasing government initiatives for biosimilars to drive growth of the biosimilars market

Increasing demand for cost-effective drugs, increasing number of geriatric population, high healthcare expenditure, increasing government support and initiatives to develop and promote biosimilars, strategic collaborations to enhance productivity and clinical trial for development of biosimilars are major factors driving growth of the market. According to the American Health and Drug Benefits in 2013, an estimated sale of biosimilars was more than US$ 1 billion annually. For instance, global sales of biosimilars was projected to reach US$ 7.19 billion for Remicade (infliximab) and US$ 5.98 billion for Avastin (bevacizumab), owing to high adoption of biosimilar drugs by doctors and patients. Furthermore, expiry and termination of pharmaceuticals drugs such as Humira, Enbrel and Remicade is providing significant opportunity for new players to enter the market.

Biosimilars Market Taxonomy

The global biosimilars market is segmented on the basis of product type, manufacturing type, application, end user, and geography.

On the basis of product type, the global biosimilars market is segmented into:

Monoclonal Antibodies

Recombinant Hormones

Anti-Inflammatory Agents

Recombinant Growth Stimulators

Immunomodulators

On the basis of by manufacturing type, the global biosimilars market is segmented into:

In-house Manufacturing

Contract Manufacturing Organizations

On the basis of application, the global biosimilars market is segmented into:

Chronic & Autoimmune Diseases

Oncology

Blood Disorders

Growth Hormone Deficiency Diseases

Infectious Diseases

Others

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/750

Availability of biosimilar drugs at cost effective rate is expected to boost growth of biosimilars market in Asia Pacific

Regional segmentation of the biosimilars market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The first biosimilar, Sandoz’s Zarxio was approved by FDA in 2015 for sale in North America. According to the American Society of Health-System Pharmacists survey in 2013, around 99% of 214 surveyed pharmacy directors reported shortage of at least one oncologic drug with distribution of biosimilars. Also, biosimilars market in North America region is expected to gain significant traction, owing to increasing prevalence of cancer, autoimmune diseases, kidney failures, and growth hormone deficiency. Biosimilar drugs provide cost effective treatment options for various diseases such as diabetes, rheumatoid arthritis and cancer, thus providing opportunities for growth of market in China and India. Furthermore, biosimilars market in Asia Pacific region is expected to witness higher growth, availability of cost effective biosimilars, high adoption rate, and consistent guidelines issued by regulatory bodies.

Key players operating in the biosimilars market include Sandoz International GmbH, Apotex, Biocon, Zydus Cadila Healthcare, Celltrion, Pfizer, Hexal, Accord Healthcare, Harvest Moon Pharmaceuticals, Eli Lilly, and Teva Pharmaceuticals. Leading manufacturers are focusing on outsourcing the production of biosimilar drugs with strategic collaborations to replace existing drugs. For instance, in August 2016, the FDA approved Sandoz for the biosimilar Erelzi for treatment of multiple inflammatory diseases such as rheumatoid arthritis, plaque psoriasis, ankylosing spondylitis and juvenile idiopathic arthritis.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: [email protected]

0 notes

rohinic123-blog · 4 years

Text

Biosimilars Market Key Opportunities and Forecast up to 2027

Biosimilars Market: Introduction

Request For Covid19 Impact Analysis –

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=118

Europe dominated the biosimilars market in 2018 and the trend is anticipated to continue during the forecast period. The strong growth of the market in the region can be attributed to increase in approvals of biosimilars in Europe. For instance, in 2018, over 16 biosimilars were approved in the region for various indications, including oncology, chronic diseases, and autoimmune diseases.

Patent Expiry of Major Biologics to Accelerate Market Growth

Patent expiries of major biologics are expected to contribute to the growth of the biosimilars market.

For instance, the U.S. patent of MabThera/Rituxan (rituximab), a biologic manufactured by Roche, expired in 2016. This provides ample growth opportunities to manufacturers of rituximab biosimilar, such as Amgen, Boehringer Ingelheim, and Pfizer. In addition, a range of top selling brands including Herceptin, Enbrel, Humalog, and Aranesp are anticipated to lose patents during the forecast period.

Planning To Lay Down Future Strategy? Request Brochure Of Biosimilars Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=118

Increase in Approvals of Biosimilars to Drive Global Market

The U.S. has witnessed a wave of biosimilar approvals in 2019. According to the Antibody Society in the U.S., over 16 antibody biosimilar therapeutics were approved from 2015 to 2019. Drugs approved in 2019 include Trazimera, Kanjinti, and Ruxience.

As per the FDA’s Biosimilars Action Plan, new policies are being made to make the development of biosimilars more efficient and provide significant opportunities to biosimilar manufacturers. This is anticipated to propel the rate of biosimilar approvals in the U.S., contributing to the growth of the biosimilars market.

High Demand for Recombinant Non-glycosylated Protein Biosimilars

To Obtain All-Inclusive Information On Forecast Analysis Of Biosimilars Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=118

Biosimilars for Oncology Indication to Dominate Global Market

Biosimilars Market: Prominent Regions

Biosimilars Market: Key Strategies

The global biosimilars market is consolidated in terms of number of players. Key players operating in the global biosimilars market include Pfizer, Inc., Intas Pharmaceuticals Ltd., Biocon, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (A Novartis Division), Celltrion Inc., Amgen, Inc., STADA Arzneimittel AG, and Apotex Inc. (Apobiologix).

These players have adopted various strategies such as product portfolio expansion, investment in research & development, collaborations, and product launches to establish a strong geographic presence. For instance, in November 2019, Pfizer received the U.S. FDA approval for its ABRILADA, a biosimilar to Humira, for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis, and plaque psoriasis.

More Trending Reports by Transparency Market Research –

Wheelchairs Market -

https://www.prnewswire.com/news-releases/wheelchairs-market-to-surpass-a-value-of-us-6-253-6-million-by-2026--says-tmr-300805704.html

Implantable Medical Devices Market -

https://www.biospace.com/article/implantable-medical-devices-market-rise-in-prevalence-of-coronary-arterial-diseases-cads-will-increase-industry-demand/

0 notes

sdmr123 · 4 years

Link

According to a study, over the next five years the Systemic Idiopathic Juvenile Arthritis Treatmentmarket will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026, from US$ xx million in 2020. In particular, this report presents the global market share (sales and revenue) of key companies in Systemic Idiopathic Juvenile Arthritis Treatmentbusiness. Systemic Idiopathic Juvenile Arthritis Treatment market development trend, sales volume and sales value (million USD) forecast in regional market, the main regions are China, USA, Europe, India, Japan, Korea, South America, Southeast Asia.

To get a free sample report:https://www.supplydemandmarketresearch.com/home/contact/1034747?ref=Sample-and-Brochure&toccode=SDMRME1034747

To get a detailed report:https://www.supplydemandmarketresearch.com/global-systemic-idiopathic-juvenile-arthritis-treatment-sales-market-1034747

#Global Systemic Idiopathic Juvenile Arthritis Treatment Sales Market size #Global Systemic Idiopathic Juvenile Arthritis Treatment Sales Market research #Global Systemic Idiopathic Juvenile Arthritis Treatment Sales Market cost #v size #Global Systemic Idiopathic Juvenile Arthritis Treatment Sales Market report #Global Systemic Idiopathic Juvenile Arthritis Treatment Sales Market demand

0 notes

marketresearchlove-blog · 4 years

Link

Xatmep market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Rising prevalence of cancer and arthritis disorders in children’s worldwide and emerging markets are the factors responsible for the growth of this market.

Growing cases of cancer such as acute lymphoblastic leukemia & idiopathic arthritis drives the Xatmep market. However, increased advancement in the treatment of cancer and rise in infant’s population with immune system diseases worldwide will boost up the global xatmep market. But, stringent FDA guidelines for the drug approval of new drug especially for children’s & adverse effect after the treatment may hamper the global xatmep market.

Xatmep is the type of folate analog metabolic inhibitor used for the treatment of paediatric patients with acute lymphoblastic leukemia & active polyarticular juvenile idiopathic arthritis as a multi-level, combinational chemotherapy regimen. Xatmep is the only FDA approved oral solution of methotrexate (2.5mg/ml) to treat paediatric patients.

#Xatmep Market #Xatmep Market forcast #Xatmep Market trade #Xatmep Market shair

0 notes

ankit2369 · 5 years

Text

U.S. Biosimilars Market 2019 Robust Expansion by Top Key Manufactures | Worldwide Overview by Size, Share, Trends, Segments

The U.S. Biosimilars Market will gain momentum from the increasing government support to adopt biosimilars in the healthcare sectors. According to a report by Fortune Business Insights, titled, “Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026,” The U.S. Biosimilars Market is projected to reach US$ 17,696.0 Mn by 2026. The report provides valuable insights into the drivers influencing growth of the market. As per the report, The U.S. Biosimilars Market is anticipated to report an impressive CAGR of 54.7% during the forecast period. The report also states that the U.S. market was valued at US$ 436.1 Mn in 2018.

Get Discount@ https://www.fortunebusinessinsights.com/enquiry/check-discount/u-s-biosimilars-market-100990

Increased Research and Development Initiatives to Drive the Market

Biosimilars are the copies of original products. Due to the high cost of pharmaceutical drugs, healthcare facilities are not accessible to people from every economical stratum. This is where biosimilars come to recuse. Being an identical copy, biosimilars help in treating chronic diseases like cancer and arthritis in an effective manner just as original medications do. The market is likely to grow during the forecast period because of an increasing demand from the masses. Also, a rise in research and development initiatives by prominent organizations have increased market opportunities. This has led to tough competition in the U.S. biosimilars market.

Browse Complete Report Details@ https://www.fortunebusinessinsights.com/industry-reports/u-s-biosimilars-market-100990

Pfizer Inc., Samsung Bioepis Co. Ltd., and Other Key Players Tend to Focus on Product Launch to Strengthen Position

Samsung Bioepis Co. Ltd, a biopharmaceutical company, received approval from Food and Drugs Administrations for ETICOVO, a biosimilar of Etanercept in April 2019. It is used for the treatment of plaque psoriasis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, and psoriatic arthritis. Pfizer Inc. a multinational pharmaceutical company based in the U.S., received approval from FDA for TRAZIMERA, a biosimilar referencing Herceptin in March 2019. It will be used to treat gastroesophageal junction adenocarcinoma and breast cancer. Earlier in July 2018, Pfizer Inc. announced that the company has received FDA approval for NIVESTYM.

It is a biosimilar to Neupogen that is approved to treat neutropenia. The FDA also granted approval for Truxima, the first biosimilar of rituximab in November 2018. It is developed by Celltrion Inc., a biopharmaceutical company headquartered in South Korea, for the treatment of non-Hodgkin’s lymphoma.

0 notes

coolluminaryland-blog1 · 6 years

Text

Etanercept Market to Perceive Substantial Growth by the End 2026

Etanercept is an injectable drug prescribed for the treatment of autoimmune diseases such as spondylitis and arthritis. Tumor necrosis factor (TNF alpha) is a protein manufactured during inflammation, the body’s response to injury. TNF alpha protein stimulates inflammation and related signs such as tenderness and swelling. Etanercept is a man-made protein that binds TNF cascade and prevents the TNF alpha from stimulating inflammatory factors. In November 1998, the U.S. Food and Drug Administration (FDA) approved etanercept. Research findings suggest that problems related to blood, immune system, seizures, and heart failure are some of the side effects associated with the usage of etanercept. However, these side effects vary from person to person.

Read Report Overview: https://www.transparencymarketresearch.com/etanercept-market.html

Lifestyle diseases are those whose occurrence is based on the daily habits of people. Usually, these diseases occur due to unsuitable relationship between people and the environment. Some of the key elements adding to list of lifestyle diseases. According to a report published by the World Economic Forum and the World Health Organization, India has incurred loss in billions of dollars in the past few years due to faulty diet and unhealthy habits. Lifestyle diseases are increasing globally and nearly one-third of the global population is likely to suffer from these in the near future. Obesity also includes patients with inflammatory arthritis. According to the same report, around 62% of the global deaths during 2006–2011 resulted from non-communicable diseases, which accounted for 45% of premature deaths. It suggested that nearly 85% of deaths will occur in low and middle income countries such as India, Malaysia, Brazil, and China in the next few year due to increase in burden of nutritional deficiencies, perinatal conditions, poor material, and infectious diseases.

The global etanercept market is projected to grow at a rapid pace during the forecast period. This is attributed to increase in incidence of obesity, lifestyle disorders, accidents, and prevalence of spondylitis. Enbrel has witnessed significant demand compared to other therapeutic proteins. It is used in the treatment of auto-immune diseases such as juvenile rheumatoid arthritis, psoriasis, and plaque. Rise in prevalence of these diseases is expected to propel the global etanercept market. Additionally, technological advancements and research and development activities could present new opportunities in the global etanercept market. However, rise in cost of overall treatment, lack of reimbursement policies in developing nations, and side effects associated with the treatment are anticipated to restrain the global market.

Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=43586

The global etanercept market can be segmented based on product and application. In terms of product, the market can be divided into Enbrel and Benepali. Based on application, the global etanercept market can be classified into ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis (JIA), and others.

Geographically, the global etanercept market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is expected to grow at a rapid pace in the next few years. The region’s dominance of the global market is attributed to favorable reimbursement scenario, acceptance of advanced techniques, and technologically advanced health care system. Europe and Asia Pacific are the other major markets for etanercept. Presence of key players, increase in investments in research and development activities by major pharma players, and collaborations of pharma and biotech companies with research institutes drive the etanercept market in these regions.

Major players in the global etanercept market include Pfizer, Inc., Immunex Corporation, Celltrion, Inc., Novartis International AG, Samsung Bioepis Co., Ltd., GlaxoSmithKline Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Ltd., and Cipla Limited.

Request For TOC : https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=43586

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Transparency Market Research 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 USA – Canada Toll Free 866-552-3453 Email: [email protected] Website: http://www.transparencymarketresearch.com/

0 notes

ionecoffman · 6 years

Text

The Meat Cleanse

“I know how ridiculous it sounds,” Mikhaila Peterson told me recently by phone, after a whirlwind of attention gathered around the 26-year-old, who is now offering dietary advice to people suffering with conditions like hers. Or not so much dietary advice as guiding people in eating only beef.

At first glance, Peterson, who is based in Toronto, could seem to be one of the many emerging semi-celebrities with a miraculous story of self-healing—who show off postpartum weight loss in bikini Instagrams and sell one thing or another, a supplement or tonic or book or compression garment. (Not incidentally, she is the daughter of the famous and controversial pop psychologist Jordan Peterson. More on that later.) But Peterson is taking the trend in extra-professional health advice to an extreme conclusion: She is not doing sponsored posts for health products, but actively selling one-on-one counseling ($75 for a half hour) for people who want to stop eating almost everything.

Peterson seems to be reaching suffering people despite a lack of training or credentials in nutrition or medicine, and perhaps because of that distinction. Her Instagram bio: “For info on treating weight loss, depression, and autoimmune disorders with diet, check out my blog or fb page!” The blog says at the top that “many (if not most) health problems are treatable with diet alone.” This is true, if at odds with the disclaimer at the bottom of the page that her words are “not intended to be a substitute for professional medical advice, diagnosis, or treatment.”

I told her I’m surprised people need further counseling, in that an all-beef diet is very straightforward.

“They mostly want to see that I’m not dead,” she said. “What I basically do is say, hey, look at all the things that happened to me and brought me to where I am now. Isn’t it weird? And then let people draw their own conclusions.”

Peterson described an adolescence that involved multiple debilitating medical diagnoses, beginning with juvenile rheumatoid arthritis. Some unknown process had triggered her body’s immune system to attack her joints. “I was unable to hold a pencil, could barely walk, and was in constant pain,” she writes on her blog, which is called “Don’t Eat That.” The joint problems culminated in hip and ankle replacements in her teens, coupled with “extreme fatigue, depression and anxiety, brain fog, and sleep problems.” In fifth grade she was diagnosed with depression, and then later something called idiopathic hypersomnia (which translates to English as “sleeping too much, of unclear cause”—which translates further to sorry we really don’t know what’s going on).

Everything the doctors tried failed, and she did everything they told her, she recounted to me. She fully bought into the system, taking large doses of strong immune-suppressing drugs like methotrexate, prednisone, leflunomide, and humira. “Despite being on multiple heavy-hitting meds, I was still struggling with basic day-to-day tasks,” she writes on her blog.

Her story takes a dramatic turn in 2015, when the underdog protagonist, nearly at the end of her rope, figured out the truth for herself. It was all about food.

Peterson adopted a common approach to dieting: elimination. She started cutting out foods from her diet, and feeling better each time. She began with gluten, and she kept going, casting out more and more—not just gluten or dairy or soy or lectins or artificial sweeteners or non-artificial sweeteners, but everything. Until, by December 2017, all that was left was “beef and salt and water,” and, she told me, “all my symptoms went into remission.”

“And you quit taking all your medications?”

“Everything.”

There is so much evidence—abundant, copious evidence acquired over decades of work from scientists around the world—that most people benefit from eating fruits, vegetables, nuts, beans, and seeds. This appears to be largely because fiber in plants is important to the flourishing of the gut microbiome. I ran this by some experts, just to make sure I wasn’t missing anything that might suggest a beef-salt diet is potentially something other than a bad idea. I learned that it was worse than I thought.

“Physiologically, it would just be an immensely bad idea,” Jack Gilbert, the faculty director at the University of Chicago’s Microbiome Center and a professor of surgery, told me during a recent visit to his lab. “A terribly, terribly bad idea.”

Gilbert has done extensive research on how the trillions of microbes in our guts digest food, and the look on his face when I told him about the all-beef diet was unamused. He began rattling off the expected ramifications: “Your body would start to have severe dysregulation, within six months, of the majority of the processes that deal with metabolism; you would have no short-chain fatty acids in your cells; most of the byproducts of gastrointestinal polysaccharide fermentation would shut down, so you wouldn’t be able to regulate your hormone levels; you’d enter into cardiac issues due to alterations in cell receptors; your microbiota would just be devastated.”

While much of the internet has been following this story in a somewhat snide way, Gilbert appeared genuinely concerned and saddened: “If she does not die of colon cancer or some other severe cardiometabolic disease, the life—I can’t imagine.”

There are few accounts of people having tried all-beef diets, though all-meat—known as carnivory—is slightly more common. Earlier this month, inspired by the media conversation about the Peterson approach, Alan Levinovitz, the author of The Gluten Lie, tried carnivory, eating only meat for two weeks. He did lose seven pounds, which he attributes to eating fewer calories overall, because he eventually got tired of eating only meat. He missed snacking at coffee shops and browsing the local farmer’s market and trying out new restaurants around town, cooking with his family, and just generally enjoying food.

“I was psychologically exhausted,” Levinovitz told me. When he returned to omnivory, and he regained the lost weight in four days.

Peterson told me it took several weeks for her to get used to the beef-only approach, and that the relief of her medical symptoms overpowers any sense of missing food. If even a tiny amount of anything else finds its way into her mouth, she will be ill, she says. This happened when she tried to eat an organic olive, and again recently when she was at a restaurant that put pepper on her steak.

“I was like, whatever, it’s just pepper,” she told me. Then she had a reaction that lasted three weeks and included joint pain, acne, and anxiety.

Apart from having to exist in a world where the possibility of pepper exposure looms, the only other social downside she notices is that she hates asking people to accommodate her diet. So she will usually eat before she goes to a dinner party, she told me, “but then I’ll go drink and enjoy the party.”

“Drink, as in, water?”

“I can also, strangely enough, tolerate vodka and bourbon.”

The idea that alcohol, one of the most well-documented toxic substances, is among the few things that Peterson’s body will tolerate may be illuminating. It implies that when it comes to dieting, the inherent properties of the substances ingested can be less important than the eater’s conceptualizations of them—as either tolerable or intolerable, good or bad. What’s actually therapeutic may be the act of elimination itself.

For centuries, ascetics have found enlightenment through acts of deprivation. As Levinovitz, who is an associate professor of religion at James Madison University, explained to me, the Daoist text the Zhuangzi describes “a spirit man” who lives in the mountains and rides dragons and subsists only on air and dew. “There’s an anti-authoritarian bent to pop-culture wisdom, and a part of that is dealing with food taboos, which are handed down by authorities,” Levinovitz said. “Those are government now, instead of religious. And because they are wrong so often—or, at least, apparently wrong—that’s a good place to go when carving out your own area of authority. If you just eat the ‘wrong’ foods and don’t die, that’s a ritual way to prove that you go against conventional wisdom.”

Peterson’s narrative fits a classic archetype of an outsider who beat the game and healed thyself despite the odds and against the recommendations of the establishment. Her story is her truth, and it can’t be explained; you have to believe. And unlike the many studies that have been done to understand the diets of the longest-lived, healthiest people in history, or the randomized trials that are used to determine which health interventions are safe and effective for whom, her story is clear and dramatic. It’s right there in her photos; it has a face and a name to prove that no odds are too long for one determined person to overcome.

The beneficial effects of a compelling personal narrative that helps explain and give order to the world can be absolutely physiologically real. It is well documented that the immune system (and, so, autoimmune diseases) are modulated by our lifestyles—from how much we sleep and move to how well we eat and how much we drink. Most importantly, the immune system is also modulated by stress, which tends to be a byproduct of a perceived lack of control or order.

If strict dietary rules provide a sense of control and order, then Peterson’s approach is emblematic of the trend in elimination dieting taken to an extreme: Avoid basically everything. This verges into the realm of an eating disorder. The National Eating Disorder Association lists among common symptoms “refusal to eat certain foods, progressing to restrictions against whole categories of food.” In the early phases of disordered eating, as with bipolar disorder or alcoholism, a person may look and feel great. They may thrive for months or even years. But this fades. What’s more, the temporary relief from anxiety may mean that the source of the anxiety goes unsought and unaddressed.

I asked Peterson about the possibility that she may be enabling people with eating disorders. She said she would draw a line if a client were underweight or inducing vomiting. Otherwise, “it’s extremely disrespectful to people with health issues caused by food to be lumped into the same category as people with eating disorders. More of the same ‘blame the patient’ stuff that doctors and health professionals already do.”

The popularity of Peterson’s narrative is explained by more than its timeless tropes; it has also been amplified by the fact that her father has occasionally cast his spotlight onto her story. Jordan Peterson’s recent book, Twelve Rules for Life, includes the story of his daughter’s health trials. The elder Peterson, a psychologist at the University of Toronto, could at first seem an unlikely face for acceptance of personal, subjective truth, as he regularly professes the importance of acting as purely as possible according to rigorous analysis of data. He argued in a recent video that American universities are the home to “ideologues who claim that all truth is subjective, that all sex differences are socially constructed, and that Western imperialism is the sole source of all Third World problems.” In his book, he writes that academic institutions are teaching children to be “brainwashed victims,” and that “the rigorous critical theoretician is morally obligated to set them straight.”

It is on grounds of his interpretation of income data, for example, that he has spoken out against the idea of a wage gap between men and women being unfair, as it can be explained away by biological factors associated with certain personality traits that are more valuable in the capitalist marketplace. From arguments from social-science evidence, he has expressed uncertainty that lesbian couples can raise children without a male father figure. And it is academic evidence that leads him to write in his book that “the so-called patriarchy” is “an arbitrary cultural artifact.”

Yet in a July appearance on the comedian Joe Rogan’s podcast, Jordan Peterson explained how Mikhaila’s experience had convinced him to eliminate everything but meat and leafy greens from his diet, and that in the last two months he had gone full meat and eliminated vegetables. Since he changed his diet, his laundry list of maladies has disappeared, he told Rogan. His lifelong depression, anxiety, gastric reflux (and associated snoring), inability to wake up in the mornings, psoriasis, gingivitis, floaters in his right eye, numbness on the sides of his legs, problems with mood regulation—all of it is gone, and he attributes it to the diet.

“I’m certainly intellectually at my best,” he said. “I’m stronger, I can swim better, and my gum disease is gone. It’s like, what the hell?”

“Do you take any vitamins?” asked Rogan

“No. No, I eat beef and salt and water. That’s it. And I never cheat. Ever. Not even a little bit.”

“No soda, no wine?”

“I drink club soda.”

“Well, that’s still water.”

“Well, when you’re down to that level, no, it’s not, Joe. There’s club soda, which is really bubbly. There’s Perrier, which is sort of bubbly. There’s flat water, and there’s hot water. Those distinctions start to become important.”

Peterson reiterated several times that he is not giving dietary advice, but said that many attendees of his recent speaking tour have come up to him and said the diet is working for them. The takeaway for listeners is that it worked for Peterson, and so it may work for them. Rogan also clarified that though he is also not an expert, he is fascinated by the fact that he hasn’t heard any negative stories about people who have started the all-meat diet.

“Well, I have a negative story,” said Peterson. “Both Mikhaila and I noticed that when we restricted our diet and then ate something we weren’t supposed to, the reaction was absolutely catastrophic.” He gives the example of having had some apple cider and subsequently being incapacitated for a month by what he believes was an inflammatory response.

“You were done for a month?”

“Oh yeah, it took me out for a month. It was awful ...”

“Apple cider? What was it doing to you?”

“It produced an overwhelming sense of impending doom. I seriously mean overwhelming. There’s no way I could’ve lived like that. But see, Michaela knew by then that it would probably only last a month.”

“A month? From fucking cider?”

“I didn’t sleep that month or 25 days. I didn’t sleep at all for 25 days.”

“What? How is that possible?”

“I’ll tell you how it’s possible, you lay in bed frozen in something approximating terror for eight hours. And then you get up.”

The longest recorded stretch of sleeplessness in a human is 11 days, witnessed by a Stanford research team.

While there is debate in the scientific community over just how much meat belongs in a human diet, it is impossible for all or even most humans to eat primarily meat. Beef production at the scale required to feed billions of humans even at current levels of consumption is environmentally unsustainable. It is not even healthy from a theoretical evolutionary viewpoint, the microbiome expert Gilbert explained to me. Carnivores need to eat meat or else they die; humans do not. “The carnivore gastrointestinal tract is completely different from the human gastrointestinal tract, which is made up of a system designed to consume large quantities of complex fibers.”

What the Petersons are selling is rather a sense of order and control. Science is about questions, and self-help is about answers. A recurring idea in Jordan Peterson’s book is that humans need rules—the subtitle of is “an antidote to chaos”—even if only for the sake of rules. Peterson discovered this through his own suffering, as when he was searching the world for the best surgeon to give his young daughter a new hip. In explaining how he dealt with Mikhaila’s illness, he writes that “existence and limitation are inextricably linked.” He quotes Laozi:

It is not the clay the potter throws,

Which gives the pot its usefulness,

But the space within the shape,

From which the pot is made

Dietary rules offer limits, good or bad, that help people define the self. This is an attractive prospect, and anyone willing to decree such rules—dietary or otherwise—is bound to attract attention. Fox News recently declared Peterson “the Left’s public enemy number one” in a segment where he discussed with Tucker Carlson “why the Left wants to silence conservative thought.” Though to have lived through the last year is to have lived in a world where Peterson and his ideas have enjoyed near-constant amplification.

The allure of a strict code for eating—a way to divide the world into good foods and bad foods, angels and demons—may be especially strong at a time when order feels in short supply. Indeed there is at least some benefit to be had from any and all dietary advice, or rules for life, so long as a person believes in them, and so long as they provide a code that allows a person to feel good for having stuck with it and a cohort of like-minded adherents. The challenge is to find a code that accords as best possible with scientific evidence about what is good and bad, and with what is best for the world.

Article source here:The Atlantic

0 notes

healthcare-research-report-blog · 6 years

Text

Systemic Juvenile Idiopathic Arthritis Treatment Market to Record Sturdy Growth by 2025

Systemic juvenile idiopathic arthritis, also termed as systemic-onset juvenile idiopathic arthritis, is a specific form of juvenile idiopathic arthritis. SJIA was also known as Still's disease. With symptoms of arthritis systemic juvenile idiopathic arthritis also shows extra-articular expression like rashes and fever. All types of arthritis involve chronic inflammation in the joints. Symptoms that last from six weeks to three months are termed chronic. Juvenile idiopathic arthritis can affect one or many joints and it can cause other symptoms such as eye inflammation. Systemic juvenile idiopathic arthritis affects around 10% children with arthritis. SJIA starts with high fever which can be 103 °C or higher, and fever can be recurring. Salmon colored rashes could also appear and disappear. Apart from inflammation of joints, SJIA can cause inflammation on internal organs. Joint inflammation may not appear until months or even after a year the fever starts. Increased white blood cells count and anemia (low red blood cells count) are also typical symptoms of SJIA. Arthritis like symptoms may present even after the fever and other symptoms disappeared.

The global Systemic Juvenile Idiopathic Arthritis Treatment Market is projected to grow at a rapid pace due to increase in prevalence of SJIA globally, also due to the available treatment and awareness between peoples are some other factors boosting the market growth. According to the Arthritis Foundation, nearly 3,000,000 children are suffering from SJIA in the U.S. A research paper published by the U.S. National Library of Medicine on SJIA, the prevalence of JIA in North America and Europe ranges from 16 to 150, and 2 to 20, per 100,000, respectively. In countries in the West, oligoarthritis is the most common sub type of JIA, while predominance of polyarthritis is more common in counties such as South Africa, New Zealand, India, and Costa Rica. A large number of children suffer from SJIA in Asia Pacific. Enthesitis-related arthritis (ERA), another sub-type of JIA, is the most common type of JIA in Canada, Mexico, and India. Rise in awareness about SJIA and available treatment is another factor boosting market growth. However, drug resistance and presence of large number of market players are the major restraints of the global systemic juvenile idiopathic arthritis treatment market.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39515

The global systemic juvenile idiopathic arthritis treatment market can be segmented based on type of treatment, end-user, and region. In terms of type of treatment, the market can be classified into NSAIDs, corticosteroids and cyclophosphamide, cyclosporine, thalidomide, and biologics. The biologics segment can be sub-segmented into IL-1 inhibitors (anakinra, rilonacept, and canakinumab), tocilizumab, abatacept, antitumor necrosis factors antibodies (anti-TNF), and rituximab. Based on end-user, the global market can be categorized into hospitals, orthopedic center, and others.

In terms of region, the global systemic juvenile idiopathic arthritis treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global market due to availability of advanced medications. Awareness among the people about the diseases is another factor boosting the market in this region. The systemic juvenile idiopathic arthritis treatment market in Asia Pacific is anticipated to expand at a high growth rate due to increase in prevalence of the disease. Lack of awareness about the disease in the underdeveloped countries in Middle East & Africa such as Turkey, Cyprus, Syria, Lebanon, and Iraq drives the systemic juvenile idiopathic arthritis treatment market.

Key players operating in the global systemic juvenile idiopathic arthritis treatment market are Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Novartis AG, Pfizer, Inc., Sanofi, F. Hoffmann-La Roche Ltd., and Amgen Inc., among others.

Enquiry for discount on this report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39515

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: [email protected]

Website: http://www.transparencymarketresearch.com

0 notes

the-rohank-blog · 6 years

Text

Explore the Scoliosis Management Market exhibiting a CAGR of 3.6% by 2028

Persistence Market Research delivers key insights on the global scoliosis management market in its upcoming outlook titled “Scoliosis Management Market: Global Industry Analysis 2013 – 2017 and Forecast 2018 – 2028”. In terms of value, the global scoliosis management market is projected to register a CAGR of 3.6% during the forecast period due to various factors, regarding which the report offers vital insights in detail. Rapidly growing demand for non-invasive treatments is expected to bolster overall growth of the scoliosis management market globally.

A sample of this report is available upon request @ https://www.persistencemarketresearch.com/samples/23569

Scoliosis Management Market: Introduction

Scoliosis is a spine disease in which the spine becomes S-shaped or C-shaped. It causes the body to look uneven from the shoulders, hips or waist. As the cause remains unknown it is called idiopathic scoliosis. The bend or the curvature can occur either in the left or the right side. Moreover, the degree of magnitude decides the treatment option for scoliosis. Exercises, braces and spinal fusion are the main treatments for scoliosis management. Generally, people suffering from scoliosis prefer using customized braces, as the treatment is less expensive as compared to surgery. The customization of the braces depends on the degree of the curvature. Scoliosis affects the lumbar, thoracic and cervical regions and it can occur in infants, juveniles and adolescents. This disease occurs due to the degeneration of spinal discs because of arthritis, osteoporosis or due to hereditary conditions. If not treated on time, the degree of curvature progresses, which can lead to difficulty in breathing.

Scoliosis Management Market: Segmentation

The global scoliosis management market is segmented on the basis of product type, age group, distribution channel and region. On the basis of product type, the market has been segmented into Cervical Thoracic Lumbar Sacral Orthosis (CTLSO), Thoracolumbosacral Orthosis (TLSO) and Lumbosacral Orthosis (LSO). Thoracolumbosacral Orthosis (TLSO) product segment is expected to register an impressive CAGR of 3.8% during the forecast period. On the basis of age group the market is segmented into infantile, juvenile and adolescents. The adolescent age group is expected to dominate the overall scoliosis management market throughout the forecast period and is expected to reach US$ 3,494.9 Mn by 2028 in revenue over the forecast period. On the basis of distribution channel, the global scoliosis management market is segmented into hospital pharmacies, retail pharmacies and online sales. In terms of distribution channel, the online sales segment is expected to witness fastest growth during the forecast period.

Scoliosis Management Market: Regional Highlights

This report covers trends driving revenue growth of each segment in the global market and offers analysis and insights of the potential treatments across the various regional markets. North America is expected to dominate the global scoliosis management market throughout the forecast period. In terms of value, Western Europe follows North America. Increasing adoption of scoliosis management products in Western Europe is marked by a high adoption rate of braces. Rise in demand for non-invasive treatments in Western Europe is expected to boost revenue growth of the scoliosis management market in the region over the forecast period.

To view TOC of this report is available upon request @ https://www.persistencemarketresearch.com/methodology/23569

Scoliosis Management Market: Key Players

The key players operating in the global scoliosis management market include Aspen Medical Products, DJO Global, Boston O&P, Trulife, Bauerfeind AG, Wellinks, Inc., Spinal Technology Inc., Horton's Orthotics & Prosthetics, Fited and Ottobock.

A large number of players operating in the global scoliosis management market are focused on entering into collaborations and partnerships with local distributors and retailers in order to enhance their market presence globally. These collaborations and partnerships enable companies to increase product visibility across different regions. Likewise, the companies in the market are focusing on investing in product innovation to strengthen their market presence worldwide.

0 notes

rohinic123-blog · 4 years

Text

Biosimilars Market to Perceive Substantial Growth by the End 2027

Biosimilars Market: Introduction

Request For Covid19 Impact Analysis –

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=118

Patent Expiry of Major Biologics to Accelerate Market Growth

Patent expiries of major biologics are expected to contribute to the growth of the biosimilars market.

Increase in Approvals of Biosimilars to Drive Global Market

Planning To Lay Down Future Strategy? Request Brochure Of Biosimilars Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=118

High Demand for Recombinant Non-glycosylated Protein Biosimilars

To Obtain All-Inclusive Information On Forecast Analysis Of Biosimilars Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=118

Biosimilars for Oncology Indication to Dominate Global Market

Biosimilars Market: Prominent Regions

Biosimilars Market: Key Strategies

More Trending Reports by Transparency Market Research –

Cardiac Arrest Treatment Market –

https://www.prnewswire.com/news-releases/increasing-lifestyle-based-disorders-to-pave-way-for-strong-growth-of-global-cardiac-arrest-treatment-market-market-to-show-4-4-cagr-during-2019-to-2027--finds-tmr-301001793.html

Healthcare API Market –

https://www.biospace.com/article/healthcare-api-market-increasing-focus-on-patient-centric-healthcare-service-by-healthcare-providers-to-be-beneficial-for-growth-tmr/

0 notes